A multicenter pilot study of antithymocyte globulin in patients undergoing allogeneic peripheral blood stem cell transplantation

INTERVENTION: Thymoglobulin (rabbit ATG), 1mg/kg, day‐2, ‐1 CONDITION: hematological malignancies PRIMARY OUTCOME: the incidences of CMV infection, hemorrhagic cystitis, and PTLD at 1 year INCLUSION CRITERIA: 1. Patients who are eligible for allogeneic stem cell transplantation (a) acute leukemia: CR1 or CR2 (b) lymphoma: PR or CR (c) MDS: IPSS int‐2 or high; WPSS high or very high 2. Age: 16‐65 years old 3. Patients who have HLA‐matched related or unrelated PBSCT donor 4. Donor age: 12‐65 years old 5. Performance status: 0‐2 6. Patients with adequate physical function (Cardiac, Hepatic, Renal, Pulmonary).